Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Cited by (1,000)

Items 701–800 of 1,000

  1. Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study
    Tanya S. Hauck, Karim Shiraz Ladha, Bernard Le Foll, Duminda Nalaka Wijeysundera, Paul A. Kurdyak · 2023 · Addiction
  2. Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads
    Beth Ann Griffin, Irineo Cabreros, Brendan K. Saloner, Adam J. Gordon, Rose Kerber, Bradley D. Stein · 2023 · Substance Abuse
  3. Association of Medication-Assisted Therapy and Risk of Drug Overdose-Related Hospitalization or Emergency Room Visits in Patients With Opioid Use Disorder
    Korosh Bahrami, Yong‐Fang Kuo, Biai Dominique Elmir Digbeu, Mukaila A. Raji · 2023 · Cureus
  4. Prescriptions for Buprenorphine in Michigan Following an Education Intervention
    Liying Chen, Sheba Sethi, Cara Anne Poland, Christopher Frank, Elizabeth Tengelitsch, Jason Elliott Goldstick, Jeremy B. Sussman, Amy S. B. Bohnert, Lewei Allison Lin · 2023 · JAMA Network Open
  5. Opioid Use Disorder in Missouri: An Evidence-Based, Public Health-Oriented Approach.
    Benjamin M. Grin · 2024 · PubMed Central
  6. Why Patients Leave: The Role of Stigma and Discrimination in Decisions to Refuse Post-Overdose Treatment
    Kassandra Frederique, Aaron Ferguson, Zoё Dodd · 2024 · The American Journal of Bioethics
  7. Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors
    Elizabeth J. Austin, Jessica A. Chen, Elena M. Soyer, Bulat T. Idrisov, Elsa S. Briggs, Lori Ferro, Andrew J. Saxon, John C. Fortney, Geoffrey Michael Curran, Yavar Moghimi et al. · 2024 · Journal of General Internal Medicine
  8. Post-traumatic stress disorder symptomatology is associated with insomnia among women engaged in opioid use disorder treatment with buprenorphine
    Hannah Stadtler, Susie Turkson, Michelle Eglovitch, Dace S. Svikis, Gretchen N. Neigh, Caitlin Eileen Martin · 2024 · Archives of Women s Mental Health
  9. A Climate of Stigma, Uncertainty, and Distrust: Stakeholder Perception of Barriers to SNF Placement for Patients with Opioid Use Disorder Treated with Methadone
    Maralyssa A. Bann, Rosie Cullen, Claas de Boer, Danielle Hrachovec, Aidan Rozler, Grant H. Blume · 2024 · Journal of General Internal Medicine
  10. Sleep Deficiency and Opioid Use Disorder
    Jennifer Langstengel, Henry Klar Yaggi · 2024 · Sleep Medicine Clinics
  11. Jail-based interventions to reduce risk for opioid-related overdose deaths: Examples of implementation within Ohio counties participating in the HEALing Communities Study
    Joel Sprunger, Jennifer L. Brown, Sofia Rubi, Joan Papp, Michael S. Lyons, Theresa M. Winhusen · 2024 · Health & Justice
  12. Buprenorphine: An anesthesia-centric review
    Thomas R. Hickey, Gregory Alexander Acampora · 2024 · Journal of Opioid Management
  13. A Spatial Epidemiologic Analysis of Opioid Use Disorder Treatment in New York State
    Ashly E. Jordan, Weihui Zhang, S. Gorry, Andrew Heck, Constance Burke, Chinazo O. Cunningham · 2025 · Medical Care
  14. Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl
    Bradley D. Stein, Flora Sheng, Brendan K. Saloner, Adam J. Gordon, Jessica S. Merlin · 2025 · Addiction Science & Clinical Practice
  15. Access to Surgery and Health Care for Justice-Involved Individuals
    D. Fletcher, K. Morgan, Kimberly Miller-Hammond, Shaneeta M. Johnson · 2025 · The American Surgeon
  16. Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel
    Tyler Jordan Varisco, James Douglas Thornton, Taha Hussain, Hannah Fish, Joshua Bolin, David Dadiomov, Ekere James Essien, Matthew A. Wanat, Diane B. Ginsburg, Jeanne Waggener et al. · 2025 · Drug and Alcohol Dependence Reports
  17. Potential uses of naltrexone in emergency department patients with opioid use disorder
    Evan Stuart Bradley, David B. Liss, Stephanie Carreiro, D. Eric Brush, Kavita M. Babu · 2019 · Clinical Toxicology
  18. Naloxone fi ll rates after opioid overdose
    AL Ruff, K Seiler, P Brady, AM Fendrick · 2019 · Journal of Addiction Medicine and Therapeutic Science
  19. Advanced Inpatient Management of Opioid Use Disorder in a Patient Requiring Serial Surgeries
    Parisa Mortaji, Dale Terasaki, Jaime Moo-Young · 2021 · Journal of General Internal Medicine
  20. Assessment and Management of Endocarditis Among People Who Inject Drugs in the General Hospital Setting
    Joji Suzuki · 2019 · FOCUS The Journal of Lifelong Learning in Psychiatry
  21. A brief report on rapid access to medication assisted treatment
    Daniel M. Baslock, Barbara Gramuglia, Alice Spirito, Javad Mashkuri, Victoria Stanhope · 2021 · Social Work in Mental Health
  22. Drug-Induced Homicide Defense Toolkit
    Valena Elizabeth Beety, Alex Kreit, Jeremiah E. Goulka, Leo A. Beletsky · 2018 · SSRN Electronic Journal
  23. The Medicaid Expansion and the Uptake of Medication-assisted Treatment for Opioid Use Disorder: Evidence from the Rhode Island All-payer Claims Database, 2012–2018
    Mary A. Burke, Riley Sullivan · 2021 · SSRN Electronic Journal
  24. Correction to: Barriers and attitudes reported by Canadian emergency physicians regarding the initiation of buprenorphine/naloxone in the emergency department for patients with opioid use disorder
    Tyson Savage, Marshall Ross · 2021 · Canadian Journal of Emergency Medicine
  25. Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals
    David Tyler Coyle, Stephanie B. Stewart, Cole Bortz, Jane Manalo, Alexis D. Ritvo, Martin Kršák · 2023 · Substance Abuse
  26. Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
    Sandra Ann Springer · 2024 · Addiction
  27. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis
    Susan L. Calcaterra, Kaylin A. Klie · 2020 · Obstetrics and Gynecology
  28. A qualitative exploration of the use of telehealth for opioid treatment: Implications for nurse‐managed care
    Omeid Heidari, Abigail K. Winiker, Sarah Pollock, Shereen Sodder, Judith I. Tsui, Karin Elizabeth Tobin · 2024 · Journal of Clinical Nursing
  29. Association Between Length of Buprenorphine or Methadone Use and Nonprescribed Opioid Use Among Individuals with Opioid Use Disorder: A Cohort Study
    Xinyi Jiang, Gery P. Guy, Jill A. Dever, John S. Richardson, Laura J. Dunlap, Didier Turcios, Sara Beth Wolicki, Mark J. Edlund, Jan L. Losby · 2024 · Substance Use & Addiction Journal
  30. Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study
    Guneet Janda, Molly M. Jeffery, Reshma Ramachandran, Joseph S. Ross, Joshua David Wallach · 2024 · BMC Medical Research Methodology
  31. Predictors of future overdose among people who inject drugs in Baltimore, Maryland
    Michael P. Ramirez, Gregory M. Lucas, Kathleen Raquel Page, Katie J. C. Zook, Miles Landry, Amanda M. Rosecrans, Robert Harris, Suzanne M. Dolwick Grieb, Oluwaseun O Falade-Nwulia, William Clarke et al. · 2024 · Drug and Alcohol Dependence Reports
  32. “The Whole Structure Is Knackered, It Could Still Explode, It Really Could”: A Mixed Methods Study of Initiatives to Increase General Practitioner Prescribing in an Opioid Dependence Treatment Program from 1970 to 2022 in New South Wales, Australia
    Hester HK Wilson, Ben Harris‐Roxas, Nicholas Lintzeris, Mark Harris · 2025 · Contemporary Drug Problems
  33. Clinical decision support as an implementation strategy to expand identification and administration of treatment of opioid use disorder in the emergency department
    Jacob A. Lebin, Stuart W Sommers, Zhixin Lun, Colin Hensen, Jason A. Hoppe · 2025 · Journal of Substance Use and Addiction Treatment
  34. Opioid overdose, suicide mortality, and premature death among veterans with alcohol or opioid use disorders: The impact of military sexual trauma
    Anne N. Banducci, Amar D. Mandavia, Michelle J. Bovin, Rachel Sayko Adams, Molly Maloney, Clara E Roth, Lauren McClain, Nicholas A. Livingston · 2025 · Addictive Behaviors
  35. Emergency Medical Services Utilization of Medication for Opioid Use Disorder: A Narrative Review of the Literature and Analysis of Prehospital Buprenorphine Protocols
    Kasha Bornstein, David Rayburn · 2025 · Prehospital Emergency Care
  36. Buprenorphine discontinuation and utilization of psychosocial services: a national study in the Veterans Health Administration
    Emma N. Cleary, Angela L. Rollins, Alan B. McGuire, Laura J. Myers, Patrick D. Quinn · 2025 · Addiction Science & Clinical Practice
  37. Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study
    Benjamin A. Howell, Anne C. Black, Hsiu‐Ju Lin, Mark A. Liberatore, Christina R. Greene, Gail D’Onofrio, Robert Heimer, Lauretta E. Grau, Kathryn F. Hawk, David A. Fiellin et al. · 2025 · Drug and Alcohol Dependence
  38. Emergency Department-Initiated Interventions for Illicit Drug Overdose
    Ruthanne Palumbo, Nancy R. Ahern, Brandy Mechling, Amany Bebawy · 2025 · Journal of Addictions Nursing
  39. Correlations between wastewater levels of naloxone and substance use disorder treatment medications with treatment encounters and overdoses – Marin County, California, USA, March 2023–June 2024
    Haylea A. Hannah, Lee Ann Prebil, Cat Condon, Jeffrey J. DeVido, Fay Zenoff, Kaitlyn Hess, Matthew Dean Willis · 2025 · Public Health
  40. Comparative effectiveness of missed dose protocols of opioid agonist treatment in British Columbia, Canada: protocol for a population-based target trial emulation
    Momenul Haque Mondol, Jeong Eun Min, Megan Kurz, Michelle Zanette, Md. Belal Hossain, Paxton Bach, Paul Gustafson, Robert William Platt, Shaun R. Seaman, Maria Eugenia Socias et al. · 2025 · BMJ Open
  41. Medicaid And Methadone For Opioid Use Disorder: Expanded Coverage Increased Distribution In 10 States, 2019–24
    Ellen Latsko, Alina Denham, Michael L. Barnett · 2025 · Health Affairs
  42. Medicaid prescription cap policies and acute care use and mortality among enrollees with opioid use disorder
    Patience M. Dow, Christopher M. Santostefano, Landon D. Hughes, Elizabeth G Stettenbauer, Theresa I. Shireman, Julie M. Donohue, Lisa Peterson, Jaclyn M. W. Hughto · 2025 · Drug and Alcohol Dependence
  43. Reach of Community-Selected Strategies to Reduce Opioid-Related Overdose Deaths in the HEALing Communities Study
    Megan E. Hall, LaShawn Glasgow, JaNae Holloway, Rouba A. Chahine, Jill Davis, Miriam T. H. Harris, Hannah K. Knudsen, Jessica L. Neufeld, Emmanuel Aja Oga, David W. Lounsbury et al. · 2025 · Substance Use & Misuse
  44. Factors associated with mortality following hospitalization among veterans with opioid use disorder
    Michael A. Incze, Sophia Huebler, Jacob D. Baylis, Andrea Stofko, Alan Taylor Kelley, Ingrid A. Binswanger, Gavin B. Bart, Andrew J. Saxon, Ajay Manhapra, Adam J. Gordon · 2025 · Journal of Substance Use and Addiction Treatment
  45. Racial and sex disparities in inpatient outcomes of patients with opioid overdose: a nationwide analysis
    Mohammed A. Quazi, Aman Goyal, Toqeer Khan, Mikel Madi, Zohaa Faiz, Alan G. Ortega Macias, Edward Davis, Amir Humza Sohail, Abu Baker Sheikh · 2025 · Baylor University Medical Center Proceedings
  46. Creation of a telehealth addiction consultation service at a rural hospital: a case study
    Rachel E. Katz, Tiarra Fisher, Talia Singer-Clark, William E. Soares, Jane Carpenter, Nadia Schuessler, Henry Stadler, Andrea C. Sahovey, Ann Scheck McAlearney, Jeffrey H. Samet et al. · 2025 · Addiction Science & Clinical Practice
  47. Extended-release Buprenorphine for Opioid Use Disorder in Hospital and Emergency Department Settings
    Megan E. Heeney, Erik S. Anderson, Lauren Roller Sirey, Robert Benard, Michelle Patregnani, Karen Lind, Amy Liang, Monish Ullal, Andrew A. Herring · 2025 · Journal of Addiction Medicine
  48. Leveraging the 72-Hour Rule Change to Support Transition From Hospital to Opioid Treatment Program
    Susan L. Calcaterra, Melissa B. Weimer, Eric Grimm, Yevgeniya Scherbak, Rawan Abdel Galil, Olivia Berger, Lindsay A. Bowman, Suzanne Amato Nesbit, Alexandra Barany, Megan E. Buresh · 2025 · JAMA Network Open
  49. A clinical trial loses access to some of its experimental treatment conditions: What can be done?
    Sarah E. Meyers-Ohki, Matisyahu Shulman, Roger D. Weiss, Patricia Novo, Scott E. Provost, Michael Christopher Otterstatter, Genie L. Bailey, John Rotrosen, Edward V. Nunes · 2025 · Journal of Substance Use and Addiction Treatment
  50. "So what's gonna happen when I get out of here?" Qualitative barriers and facilitators to MOUD continuity post-release from jail
    Thomas J. Stopka, Rebecca E. Rottapel, Morgan Ruggiro, Claudia Santelices, Peter D. Friedmann, Ekaterina Pivovarova, Elizabeth Evans · 2026 · Drug and Alcohol Dependence
  51. Screening and interventions for substance use in primary care
    Michelle Knapp, Donna E. McCabe · 2019 · The Nurse Practitioner
  52. Addressing multiple overdoses: Opportunities for prevention and innovation
    Sarah Mary Bagley, Scott Evan Hadland · 2021 · International Journal of Drug Policy
  53. Moving Upstream: A Social Emergency Medicine Approach to Opioid Use Disorder
    Elizabeth A. Samuels, Kelly M. Doran · 2021 · Annals of Emergency Medicine
  54. Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial
    Grace E. Janzow, Cassandra Harding, Michael William Flores, Jacob T. Borodovsky, Jackson Steinkamp, Lisa A. Marsch, Zev Schuman‐Olivier · 2022 · Drug and Alcohol Dependence Reports
  55. Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19
    Katherine L. Potaka, Rebecca Freeman, Danny Soo, Nam‐Anh Nguyen, Tin Fei Sim, Joanna C. Moullin · 2022 · BMC Emergency Medicine
  56. Medication for opioid use disorder at hospital discharge is not associated with intravenous antibiotic completion in post-acute care facilities
    Edward C Traver, Patrick R Ching, Shivakumar Narayanan · 2022 · Therapeutic Advances in Infectious Disease
  57. C-L Case Conference: Applying Good Psychiatric Management for Borderline Personality Disorder in Hospitalized Patients With Co-occurring Substance Use Disorders
    Barrington J. Hwang, Brandon T. Unruh, Kristopher A. Kast · 2022 · Journal of the Academy of Consultation-Liaison Psychiatry
  58. Better care at the bedside for hospitalized patients with opioid use disorder
    Susan L. Calcaterra, Megan E. Buresh, Melissa B. Weimer · 2023 · Journal of Hospital Medicine
  59. The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
    Kaley Parchinski, Angela Di Paola, Allison Wilson, Sandra Ann Springer · 2023 · Drug and Alcohol Dependence Reports
  60. Evaluation of the New England Office Based Addiction Treatment ECHO: A Tool for Strengthening the Addiction Workforce
    Matthew R. Heerema, Alicia S. Ventura, Samantha Blakemore, Iván D. Montoya, Danna E. Gobel, Mathew Vinhhoa Kiang, Colleen T. LaBelle, Angela R. Bazzi · 2023 · Substance Abuse
  61. Correlates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment
    Uzoji Nwanaji-Enwerem, Mark Beitel, David E. Oberleitner, Marina Gaeta Gazzola, Kathryn F. Eggert, Lindsay Oberleitner, Oluwole O Jegede, Xiaoying Zheng, Nancy Schmieder Redeker, Lynn M. Madden et al. · 2023 · Journal of Psychoactive Drugs
  62. High-deductible Health Plans and Nonfatal Opioid Overdose
    Julia C. P. Eddelbuettel, Colleen L. Barry, Alene Kennedy‐Hendricks, Alisa B. Busch, Mara A.G. Hollander, Haiden A. Huskamp, Mark Katz Meiselbach, Cameron J. Schilling, Elizabeth A. Stuart, Matthew D. Eisenberg · 2023 · Medical Care
  63. Unfilled prescriptions: Surveying patients' experiences with buprenorphine treatment in Massachusetts before and during the COVID‐19 pandemic
    Joseph A. Rosansky, Mark A. Albanese, Joshua Phillips, Zev Schuman‐Olivier · 2023 · American Journal on Addictions
  64. Contributions of a central registry to monitor methadone treatment through the HEALing Communities Study
    Katherine R. Marks, Jeffery Talbert, Lindsey Robertson Hammerslag, Michelle R. Lofwall, Laura C. Fanucchi, Holly Broce, SHARON L. WALSH · 2023 · Journal of Opioid Management
  65. Buprenorphine and Opioid Use Disorder Training: Graduate Nursing Curricula Recommendations
    Lauren Meadows, Amanda J. Simonton, Donna G. Rolin · 2023 · Journal of Psychosocial Nursing and Mental Health Services
  66. Sleep Deficiency and Pain in Persons With Substance Use Disorders
    Michele J. Buonora, Mehak Sharma, Caroline G. Falker, Stephen R. Baldassarri · 2024 · Current Addiction Reports
  67. National- and State-Level Pharmacy-Based Buprenorphine Dispensing, United States 2019–2021
    Chase L. Barham, Andrea E. Strahan, Kun Zhang, Gery P. Guy · 2024 · Journal of General Internal Medicine
  68. Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study
    Corey J. Hayes, Rebecca A. Raciborski, Bradley C. Martin, Adam J. Gordon, Teresa J. Hudson, Clare C. Brown, George C. Pro, Michael A. Cucciare · 2024 · Journal of Substance Use and Addiction Treatment
  69. Latine perspectives on the impact of family, perceptions of medication, health systems, incarceration, and housing on accessing opioid agonist therapy: A thematic analysis
    Karina Ascunce, Natalie Swartz, Miguel A Linares, Camila Gelpí-Acosta, Avik Chatterjee · 2024 · Journal of Substance Use and Addiction Treatment
  70. Influences of the criminal justice system on use of medications for opioid use disorder: a qualitative study
    Emmeline N. Taylor, Caroline P. Gray, Matthew A. Stimmel, Ingrid A. Binswanger, Erica Ferro Morse, Christine Timko, Alex H. S. Harris, David A. Smelson, Andrea K. Finlay · 2024 · BMC Global and Public Health
  71. Filling the Treatment Gap: Geographic Expansion of Buprenorphine Providers Across the U.S.
    Suparna Das, Kasimu Muhetaer, Neeraj Gandotra, Naomi Tomoyasu · 2024 · AJPM Focus
  72. Bridging the gap: An environmental scan of post-overdose program features and evaluation measures
    Mikayla Ferg, Sabrina S. Rapisarda, Elena Soranno, Nikki M. Lewis, Andy Ottoson, Cynthia A. Tschampl · 2024 · International Journal of Drug Policy
  73. Barriers to and facilitators of buprenorphine dispensing for opioid use disorder: Evidence from focus groups in Appalachian Kentucky
    Douglas R. Oyler, Dustin K. Miracle, Hannah Hesener, Laura K. Stinson, Monica F. Roberts, Adrienne W. Matson, Patricia Rippetoe Freeman · 2024 · Journal of the American Pharmacists Association
  74. Telehealth and disparities in opioid use disorder treatment: Medicaid enrollees versus privately insured individuals
    Lindsay Allen, Melinda Xu · 2024 · Health Services Research
  75. Examining how support persons’ buprenorphine attitudes and their communication about substance use impacts patient well-being
    Jasmin Choi, Lane F. Burgette, Katherine Nameth, Katherine E. Watkins, Karen Chan Osilla · 2025 · The American Journal of Drug and Alcohol Abuse
  76. Exploring Preferences for Communication and Care Among Hospitalized Patients With Opioid Use Disorder: A Qualitative Descriptive Study
    M Holliday Davis, Rachel French, Molly Crowe, Matthew Phillip Abrams, Grace Edwards, Shoshana V. Aronowitz, David S. Mandell, Margaret Lowenstein · 2025 · Journal of Addiction Medicine
  77. Buprenorphine adherence among a prospective cohort of homeless-experienced adults with opioid use disorder
    Danielle R. Fine, Natalia Critchley, Katherine Hart, Susan Regan, Nora J. Sporn, Jessie M. Gaeta, Joe Wright, Gina Rae Kruse, Travis P. Baggett · 2025 · Drug and Alcohol Dependence
  78. A multi-method spatial examination of factors associated with changes in geographic accessibility to buprenorphine providers in HEALing communities study states Kentucky, Massachusetts, and Ohio
    Shikhar Shrestha, Olivia Lewis, Daniel R. Harris, Peter J. Rock, Anita Silwal, Sumeeta Srinivasan, Thomas J. Stopka · 2025 · Preventive Medicine Reports
  79. Recruiting opioid treatment program administrators for a national survey: Outcomes and lessons learned
    Benjamin R. Brady, Beth E. Meyerson, Alissa Davis, Gregory A. Carter, Sara M Najar, Alexa Martinez, Caleb Mueller, Elias O Higbie, Holden Dal Ponte, Khino Moneva et al. · 2025 · International Journal of Drug Policy
  80. Buprenorphine or methadone: A single‐center survey of patient preference in an urban emergency department
    Corey S. Hazekamp, Austin J. Parish, Anthony D. Scoccimarro · 2025 · Academic Emergency Medicine
  81. Exploring passion for opioid use with a treatment-seeking sample: results from a canonical correlation analysis
    Brandon Park, Alan K. Davis, Cecilia L. Bergeria, Yitong Xin · 2025 · Addiction Research & Theory
  82. Differential Changes in Use of Medications for Opioid Use Disorder by Race-Ethnicity: Effects of a Hub-and-Spoke Model
    Maureen T. Stewart, Shay M. Daily, Lee Panas, Sage R. Feltus, Margaret Lee, Grant A. Ritter, Sharon Reif · 2025 · Psychiatric Services
  83. Extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose: The FASTER-BUP udy
    Maria Eugenia Socias, Piper Dickhout, Jenna Langlois, Cameron J Grant, Seonaid Nolan · 2025 · Drug and Alcohol Dependence
  84. Implications of epidemic-pandemic convergence for routine care adoption of contingency management: A case study.
    Sean D. Regnier, Anthony DeFulio · 2022 · Experimental and Clinical Psychopharmacology
  85. Case 6-2019: A 29-Year-Old Woman with Nausea, Vomiting, and Diarrhea
    Alexander Yale Walley, Sarah E. Wakeman, George M. Eng · 2019 · New England Journal of Medicine
  86. The role of the defense attorney in relation to biological interventions as rehabilitative strategies
    Colleen M. Berryessa, Jennifer A. Chandler · 2020 · Journal of Offender Rehabilitation
  87. ACMT Position Statement: Allow Optimal Treatment for Healthcare Professionals with Opioid Use Disorder
    Ryan T. Marino, Meghan Beth Spyres, Timothy J. Wiegand, Kavita M. Babu, Andrew Ian Stolbach · 2021 · Journal of Medical Toxicology
  88. Brief report: Cause of death among people discharged from infective endocarditis related hospitalization—West Virginia, 2016–2019
    Zheng Dai, Gordon Stephen Smith, Brian M. Hendricks, Ruchi Bhandari · 2022 · Clinical Cardiology
  89. Toward evaluation of disseminated effects of medications for opioid use disorder within provider‐based clusters using routinely‐collected health data
    Ashley L Buchanan, Tianyu Sun, Jing Hui Wu, Hilary A. Aroke, Jeffrey P. Bratberg, Josiah D. Rich, Stephen J Kogut, Joseph W. Hogan · 2022 · Statistics in Medicine
  90. A Retrospective Comparison of the Effectiveness of Buprenorphine Versus Baclofen for Acute Opioid Withdrawal
    Matthew Hermenau, Benton Stamper, Kitty Leung, Raymond Pomm, Christina Guerrier, Joseph Cammilleri, Brittany Johnson · 2023 · HCA Healthcare Journal of Medicine
  91. Implementation of an education session on buprenorphine induction in the emergency department, a resident-led initiative
    Cara Marie Borelli, Han Tony Gao · 2024 · Harm Reduction Journal
  92. Homeless people’s experiences of the illicit drug supply during COVID-19
    Susanna James, Nick Maguire · 2024 · Housing Care and Support
  93. Buprenorphine, not naloxone, as first-line rescue medication for patients with cancer-associated pain on chronic opioid therapy complicated by respiratory depression: A realist review
    Aaron K. Livingston, Jason A. Webb · 2024 · Progress in Palliative Care
  94. Requiring Buprenorphine Waivers for Psychiatry Residents
    Nathaniel P. Morris, Brandon S. Bentzley · 2018 · Academic Psychiatry
  95. Can Extended-release Injectable Medications Help Curb United States and Canada's Opioid Overdose Epidemic?
    Socías, M. Eugenia, Nolan, Seonaid · 2021 · Journal of Addiction Medicine
  96. Substance Use Disorder and HIV
    Deepika E. Slawek, Chinazo O. Cunningham · 2020 · Springer eBooks
  97. Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder
    Fulton F Velez, Danmeng Huang, Lorie Mody, Daniel C. Malone · 2021 · Expert Review of Pharmacoeconomics & Outcomes Research
  98. Hospital-Based Services for Opioid Use Disorder: A Study of Supply-Side Attributes
    Kelsey C. Priest · 2000
  99. Balancing Benefits and Harms on the Frontier of Buprenorphine Initiation
    Reuben J. Strayer, Andrew A. Herring, Lewis S. Nelson · 2019 · Annals of Emergency Medicine
  100. Addressing Opioid Use Disorder in Primary Care: Revisiting Core Primary Care Principles to Confidently Initiate Treatment
    Jarratt D. Pytell, Ingrid A. Binswanger · 2024 · Journal of General Internal Medicine